MA
RXRX icon

MCF Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

MCF Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4K Buy
+7,465
New +$24.9K ﹤0.01% 813

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MCF Advisors's RXRX Position: Q2 2026 in Review

MCF Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 7,465 shares worth $27.4K. The stake represents ﹤0.01% of the portfolio and ranks #813 among its holdings.

342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • MCF Advisors held 7,465 shares of Recursion Pharmaceuticals worth $27.4K as of Q2 2026.
  • Recursion Pharmaceuticals was a new MCF Advisors position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #813 holding.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.